252 related articles for article (PubMed ID: 26397968)
1. Personal opinion: Treatment of vulvovaginal atrophy--are hidden interests and misinformation preventing better management?
Pines A; Sturdee DW
Climacteric; 2015; 18(6):802-4. PubMed ID: 26397968
[TBL] [Abstract][Full Text] [Related]
2. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
3. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
Kingsberg SA; Wysocki S; Magnus L; Krychman ML
J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
[TBL] [Abstract][Full Text] [Related]
4. WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history.
Kingsberg SA; Larkin L; Krychman M; Parish SJ; Bernick B; Mirkin S
Menopause; 2019 Feb; 26(2):124-131. PubMed ID: 30130293
[TBL] [Abstract][Full Text] [Related]
5. Vulvovaginal atrophy: new and upcoming approaches.
Simon JA
Menopause; 2009; 16(1):5-7. PubMed ID: 19131842
[No Abstract] [Full Text] [Related]
6. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
Reid RL; Black D; Derzko C; Portman D
J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
[TBL] [Abstract][Full Text] [Related]
7. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Tan O; Bradshaw K; Carr BR
Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
[TBL] [Abstract][Full Text] [Related]
8. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
9. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10μg estradiol on symptoms of vulvovaginal atrophy.
Archer DF; Labrie F; Montesino M; Martel C
J Steroid Biochem Mol Biol; 2017 Nov; 174():1-8. PubMed ID: 28323042
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
12. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial.
Paraiso MFR; Ferrando CA; Sokol ER; Rardin CR; Matthews CA; Karram MM; Iglesia CB
Menopause; 2020 Jan; 27(1):50-56. PubMed ID: 31574047
[TBL] [Abstract][Full Text] [Related]
14. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
Edwards D; Panay N
Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
[TBL] [Abstract][Full Text] [Related]
15. Update on management of genitourinary syndrome of menopause: A practical guide.
Palacios S; Castelo-Branco C; Currie H; Mijatovic V; Nappi RE; Simon J; Rees M
Maturitas; 2015 Nov; 82(3):308-13. PubMed ID: 26261035
[TBL] [Abstract][Full Text] [Related]
16. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
North American Menopause Society
Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
[TBL] [Abstract][Full Text] [Related]
17. Iranian postmenopausal women's experiences of treatment of symptomatic vulvovaginal atrophy.
Fooladi E; Deldar M; Mohammadzadeh F; Ahmadnia E; Khani S; Ghanbari Z
Climacteric; 2017 Feb; 20(1):67-71. PubMed ID: 28064523
[TBL] [Abstract][Full Text] [Related]
18. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.
Potter N; Panay N
Climacteric; 2021 Feb; 24(1):19-24. PubMed ID: 32990054
[TBL] [Abstract][Full Text] [Related]
19. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview.
Sinha A; Ewies AA
Climacteric; 2013 Jun; 16(3):305-12. PubMed ID: 23215675
[TBL] [Abstract][Full Text] [Related]
20. Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations.
Lev-Sagie A
Clin Obstet Gynecol; 2015 Sep; 58(3):476-91. PubMed ID: 26125962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]